Karyopharm Therapeutics Inc.KPTINASDAQ
Loading
Cost of Revenue Over TimeContracting
Percentile Rank43
3Y CAGR+4.5%
5Y CAGR+17.1%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
+4.5%/yr
vs -57.6%/yr prior
5Y CAGR
+17.1%/yr
Recent deceleration
Acceleration
+62.1pp
Accelerating
Percentile
P43
Within normal range
vs 5Y Ago
2.2x
Strong expansion
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $5.95M | -1.0% |
| 2024 | $6.01M | +21.5% |
| 2023 | $4.94M | -5.2% |
| 2022 | $5.21M | +53.2% |
| 2021 | $3.40M | +25.8% |
| 2020 | $2.71M | +12.4% |
| 2019 | $2.41M | -98.5% |
| 2018 | $161.37M | +50.4% |
| 2017 | $107.27M | +23.4% |
| 2016 | $86.94M | - |